INTRODUCTION
Vitamin D was discovered based on its role as an antirachitic agent and it is now well understood that vitamin D deficiency results in rickets in adolescents and osteomalacia in adults. 1 Regulation of calcium and phosphate by vitamin D is widely studied and it is known to have a major role in maintaining a healthy skeleton. Conversely, vitamin D deficiency on bone in vivo can be compensated by the administration of calcium and phosphate. There is also growing evidence that vitamin D has a direct effect on bone cells; osteoblasts, osteocytes, and osteoclasts. [2] [3] [4] In vitro studies have revealed that osteoblasts and osteocytes can locally synthesize the active metabolite 1,25(OH) 2 D 3 as they express CYP27B1, as well as having the ability to locally catabolize vitamin D by expressing the CYP24A1 enzyme. 5 Peripheral blood mononuclear cell (PBMC)-derived osteoclasts have been shown to express CYP27B1 and are capable of metabolizing 25(OH)D 3 into 1,25(OH) 2 D 3 , suggesting that metabolism of vitamin D has a role in osteoclast differentiation. [6] [7] The level of CYP27B1 transcript expression has been shown to increase during RANKL-induced osteoclast differentiation in PBMCs as well as in RAW 264.7 murine cell line. [7] [8] Our current understanding of the effect of 1,25(OH) 2 D 3 on osteoclast behavior is that 1,25(OH) 2 D 3 promotes formation, but inhibits the resorptive activity of mature osteoclasts derived from human PBMCs and murine cell line RAW 264.7. 9 The action of vitamin D on the reduction of osteoclastogenesis is not well defined, but it has been suggested that the metabolism of 25(OH)D 3 into 1,25 (OH) 2 D 3 reduces osteoclast resorptive capacity by the modification of cellular adhesion and a reduction in the migration of resorptive osteoclasts. 10 It has further been proposed that the action of 1,25(OH) 2 D 3 on bone resorption might be by an increase in the proliferation of the precursors of osteoclasts.
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It has been reported that VDR is not expressed by mature osteoclasts in vivo human tissues, but rather in osteoclast precursors. [12] [13] Stimulation of osteoclast formation by 1, 25 (OH) 2 D 3 has been shown to be by the upregulation of RANKL in osteoblasts and osteocytes and a direct cellto-cell contact between osteoclast precursors and osteoblasts. 14 Osteoclast function can be blocked by osteoprotegerin, a decoy receptor for RANKL, and osteoprotegerin has been shown to be downregulated in osteoblasts by 1,25(OH) 2 D 3 .
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Vitamin D metabolites have been used as therapeutic drugs for the treatment of osteoporosis, as bone mass density has been shown to increase in these patients. 18 Paradoxically, suppression of bone resorption should lead to an increase in bone mass density. Several studies have been conducted to elucidate the effect of vitamin D on osteoclasts in vivo; however, the effects have been reported as both inhibitory and stimulatory, and the exact mechanisms remain unknown. 19 In in vitro studies (doses of more than 1 nmol·L
), 1,25(OH) 2 D 3 has been shown to have both stimulatory as well as inhibitory effects on osteoclast activity. [19] [20] [21] [22] In co-culture studies of osteoblasts and hematopoietic cells, active metabolites of vitamin D has been shown to stimulate osteoclastogenesis. [23] [24] [25] This stimulation has been shown to be an increase in RANKL production and consequently osteoclast stimulation. Hence, 1,25(OH) 2 D 3 has been believed to directly stimulate osteoclast resorption. As the active metabolites of vitamin D has been used therapeutically, the increase in bone mass density in osteoporotic patients has been assumed to be suppression of bone resorption. Thus, the effects of 1,25(OH) 2 D 3 on osteoclast bone resorption in in vitro studies seem to be opposite to in vivo studies. ethylenediaminetetraacetic acid (Lonza, UK) solution over 6 weeks, and embedded in paraffin. Paraffin-embedded human bone samples (nonpathological) were kindly provided by Dr Kashima Takeshi, Pathology Department, Nuffield Orthopaedic Centre, University of Oxford. Bone samples were cut in serial sections at 5 μm and mounted on adhesive glass slides (Lecia Biosystems, Milton Keynes, UK). Slides were deparaffinised in xylene and rehydrated through a graded series of alcohols to water. Slides were washed with tris-buffered saline and Tween 20 (TBST), and endogenous peroxidase activity was quenched by 3% hydrogen peroxide for 30 min. Antigen retrieval was performed on an 85°C hot plate using citrate buffer for 10 min. Non-specific reactivity was blocked in TBST-5% bovine serum albumin for 30 min at room temperature. Representative slides were incubated overnight at 4°C with mouse anti-human VDR monoclonal antibody (Santa Cruz Biotechnology, Heidelberg, Germany) or for 1 h with mouse anti-human cathepsin K monoclonal antibody (Merck Millipore, Hertfordshire, UK) at a dilution of 1:200 and 1:400, respectively.
MATERIALS AND METHODS

Reagents and chemicals
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After primary antibody incubation reaction, secondary biotinylated rabbit anti-mouse antibody (Vector Laboratories, Peterborough, UK) was applied for 30 min at room temperature. Sections then were rinsed with TBST, and visualized using the avidin-biotin peroxidise diluted at 1:200 for 30 min. Sections were rinsed with TBST and treated with 3,3-diaminobenzidine (Vector Laboratories). Sections were counterstained with hematoxylin for 10 s, washed under running water for 30 s, dehydrated in ethanol, cleared in xylene, and cover slipped with Dibutylphthalate Polystyrene Xylene mounting medium. Sections were examined using an Olympus BX40 light microscope (Philadelphia, PA, USA) and photographs were captured at × 4-20 magnifications. For general morphological analysis, decalcified sections were stained with Mayer's hematoxylin and eosin, and negative control sections were incubated with the non-immunized mouse IgG2a and IgG1 (R&D Systems, UK).
Cell sorting Buffy coats enriched of CD14+ monocytes were obtained from Oxford Radcliffe Biobank (Oxford, UK), and cell sorting was performed using the Magnetic-activated cell sorting (MACS) column separation kit according to the manufacturer's instructions (Miltenyi Biotec, Surrey, UK). Buffy coats were diluted in a 1:1 ratio in α-minimal essential medium (Invitrogen, Paisley, UK), layered over Histopaque and centrifuged (750 g) for 25 min. The interface layer was resuspended in α-minimal essential medium and then centrifuged (600 g) for a further 10 min. The resultant cells were incubated with MACS CD14+ microbeads (Miltenyi Biotec) for 20 min at 4°C, passed through MACS magnetic column separator, and resuspended in medium supplemented with 10% heat-inactivated charcoal-stripped serum (CSS; Sigma-Aldrich) and the cells were counted by hemocytometer.
Osteoclast formation assay To assess the extent of osteoclast formation, isolated human CD14+ cells were cultured in 24-well plates (1 × 10 6 ) and maintained in 1 ml α-minimal essential medium-CSS with 25 ng·mL − 1 recombinant human M-CSF (R&D Systems) and ) in ethanol as vehicle (total added volume was o1% of the culture medium volume). Osteoclast culture media containing the vitamin D metabolites were changed every other day up to 6 days before RNA and 14 days for protein extraction.
After 6 days in culture, the expression of TRAP in the cultures was examined histochemically. The culture plates were rinsed in phosphate-buffered saline, fixed with 4% formaldehyde for 10 min, and rinsed in distilled water. TRAP was histochemically revealed by a simultaneous coupling reaction using Naphtol AS-BI-phosphate (Sigma-Aldrich, Dorset, UK) as a substrate and Fast violet B (Sigma-Aldrich, Dorset, UK) as the diazonium salt. The wells were then incubated for 60 min at 37°C in the dark, rinsed three times in distilled water, and the residual activity was inhibited by 4 % NaF for 30 min. TRAP-positive cells, with more than three nuclei, were identified as osteoclasts. The number of generated osteoclasts were assessed using light microscopy. The size of the osteoclasts was determined by image analysis using the ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Osteoclast resorption assay
To assess the extent of resorption, human CD14+ cells were cultured in 96-well plates on 3 mm dentin slices. Cells were maintained in osteoclast culture media and treated every other day in the presence or absence of 25(OH)D 3 (100 or 500 nmol·L RT-PCR was performed using a ViiA7 system (Applied Biosytems) with commercially available lyophilized QuantiTect Qiagen primers: vdr, cyp27b1, cyp24a1, nfatc1, and tm7sf4. A volume of 1 μL of one-twentieth dilutions of templates were used in a total volume of 10 μl reaction in 384-well plates (Applied Biosystems) by two-step cycling (polymerase activation at 95°C for 2 min, 40 cycles of template denaturation at 95°C for 5 s, and primer annealing and extension at 65°C for 30 s) using SYBR green Master Mix (SensiFAST SYBR Lo-Rox kit, Bioline, London, UK). The C t values for treated samples were normalized to housekeeping genes gapdh and the relative expressions were calculated using ΔΔ C t with amplification and accuracy of 98%-100%.
Statistical analysis
All experiments were carried out at least in triplicates and the mean ± s.e.m. was calculated. Statistical analyses were carried out using SPSS version 11.0 for windows (SPSS, Chicago, IL, USA). Effects of vitamin D treatments in respect to untreated cells were compared by Student's t-test and a P value of o0.05 was regarded to indicate a significant difference.
RESULTS
Immunohistochemistry VDR immunoreactivity in human bone tissue was observed in bone lining osteoblasts (Figure 1a , black arrows) and newly embedded osteocytes (Figure 1a , white arrows), but not in mature osteocytes (Figure 1c, red arrows) , adipocytes (Figure 1a , red arrows), and chondrocytes (Figure 1b , black arrows). Multinucleated osteoclasts on the bone surfaces with clear lacunar pit (Figure 1c , black arrow) also showed VDR immunoreactivity. Immunohistochemical staining of serial sections revealed that osteoclasts also were immune-reactive for cathepsin K (Figure 1d , black arrows). There was no staining of VDR or cathepsin K in serial sections exposed to non-immunized mouse IgG negative (Figure 1a -d, middle images).
Western blotting
To assess the expression of VDR in vitro cell cultures, cell lysates of human osteoclasts as well as other in-house bone cell lysates were assessed by western blotting. VDR protein was expressed in all cell lysates; human osteoclast precursor, differentiated osteoclasts, human and mouse osteoblast, and mouse osteocyte-like cell lysates as well as HL-60 control sample (Figure 2a) , with highest expression in MLO-Y4 and MLO-A5 osteocyte-like cell lines and lowest expression in SaOS-2, MC3T3 osteoblasts, and human osteoclast precursor.
Effect of vitamin D metabolites on vitamin D-related genes
The effects of vitamin D metabolites during osteoclastogenesis on vitamin D metabolic pathway genes was examined by qRT-PCR. Initially, we tested the effects of M-CSF or RANKL-M-CSF for the generation of osteoclasts, where 6 days of RANKL-M-CSF generated maximal number of multinucleated osteoclasts (Figure 2b ). The data revealed that osteoclasts express VDR, CYP27B1, and CYP24A1 at messenger RNA level. VDR messenger RNA expression was not altered in response to 500 nmol·L (100 and 500 nmol·L − 1 ) or 1,25(OH) 2 D 3 (0.1 and 0.5 nmol·L − 1 ) over 6 days for TRAP staining or 14 days for resorption. After 6 days, the expression of TRAP in the cultures was examined histochemically, images were taken by Zeiss AX10 microscope (Carl Zeiss, Jena, Germany) and number of positive cells (a) with greater or less than eight nuclei were counted manually (e). After 14 days, the dentine slices were removed from the 96-well plates, placed in 1 mol·L − 1 NH 4 OH for 30 min and sonicated to remove adherent cells. Dentins were rinsed in distilled water, air dried, and images were captured by light microscopy (b). Dentins were stained with toluidine blue, photographed (c), and resorption areas per dentin slice (f) (μm 2 )
were analyzed with ImageJ software (National Institutes of Health Osteoclast resorption has been reported in response to 25(OH)D 3 or its active metabolites, whereas we have shown an increase in osteoclast in response to both metabolites. 7, 19 This opposite effect could be due to a number of points of difference in the materials used for this study. Of particular, importance is the substantially lower doses of 1,25 (OH) 2 D 3 with respect to the literature, which reports doses in the range of 1-100 nmol·L Another source of difference to the majority of previous studies may be the use of CD14+ cells rather than PBMCs, and combined rather than separate treatments of RANKL and M-CSF. This selective isolation of osteoclast precursor cells that are committed to differentiate in response to RANKL-M-CSF factors, may produce a different 'bulk' response to PBMCs (containing~10% precursor).
In 
